New GLP-1 Manufacturing Facility (Europe, launch 2028) Estimated value: +5 PLN per share Celon Pharma’s strategic plan to launch a GLP-1 production facility in Europe by 2028 is a substantial value catalyst. Assumptions include: scalable GMP production tailored to the fastest-growing therapeutic segment globally, attractive economics from contract manufacturing (CDMO) for GLP-1 analogs, strong demand visibility for European supply due to constraints at Novo Nordisk and Eli Lilly, margin uplift from high-value biologics processing.Read more